Hanze Zhang
Overview
Explore the profile of Hanze Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu X, Wang H, Lu Y, Zhang H, Tan T, Xu F, et al.
Artif Intell Med
. 2025 Feb;
162:103096.
PMID: 39999658
Background And Objectives: Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among people over 50 years old, which manifests in the retina through various changes of...
2.
Qu Y, Ma J, Di R, Bian Y, Li Y, Zhang H, et al.
BMC Ophthalmol
. 2024 Dec;
24(1):529.
PMID: 39695526
Background: This study was to evaluate the features of choroidal Sattler's and Haller's layer (CSHL) vessels in adults and explore its relationship with factors such as age, axial length (AL)...
3.
Zhang L, Fang K, Zhang H, Wang X, Huang F
Langmuir
. 2024 Nov;
40(49):26292-26302.
PMID: 39591590
Metal-containing dyes in the textile industry release heavy metal ions into wastewater, posing significant environmental risks and complicating treatment processes. Among various removal methods, chemical adsorption through functional groups that...
4.
Zhang H, Zhang N, Li Z, Yang J, Zhu Y, Liu Z, et al.
Sci Rep
. 2024 Oct;
14(1):23824.
PMID: 39394394
This study aims to assess how the construction patterns within residential communities influence the adolescent myopia using general survey. In a private high school from a megacity in mid-west China,...
5.
Yuan L, Li Y, Zhang H, Hou Y, Kang Q, Lei J
J Ophthalmic Inflamm Infect
. 2024 Sep;
14(1):46.
PMID: 39347877
Background: To report a case of Bilateral Purtscher-like retinopathy associated with DRESS syndrome managed with ocular and systemic treatments. Case Presentation: A 29-year-old healthy female developed multi-organ (cutaneous, hematologic, renal...
6.
Liu S, Yang S, Zhang H, Wu W
Sensors (Basel)
. 2023 Feb;
23(4).
PMID: 36850846
With the rise of latency-sensitive and computationally intensive applications in mobile edge computing (MEC) environments, the computation offloading strategy has been widely studied to meet the low-latency demands of these...
7.
Trivedi A, Sohn W, Hsu C, Jafarinasabian P, Zhang H, Hutton S, et al.
Clin Pharmacol Drug Dev
. 2021 Oct;
11(3):388-396.
PMID: 34634185
Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and...
8.
Trivedi A, Sohn W, Kulkarni P, Jafarinasabian P, Zhang H, Spring M, et al.
Clin Transl Sci
. 2021 Aug;
14(6):2510-2520.
PMID: 34415673
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is...
9.
Trivedi A, Sohn W, Jafarinasabian P, Zhang H, Terminello B, Flach S, et al.
Clin Pharmacol Drug Dev
. 2021 Jul;
11(1):129-133.
PMID: 34272833
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is administered as a 25-, 37.5-, or...
10.
Trivedi A, Malik F, Jafarinasabian P, Zhang H, Flach S, Abbasi S, et al.
Clin Pharmacol Drug Dev
. 2021 Jun;
11(2):185-193.
PMID: 34145992
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The effect of CYP3A4 and CYP2D6 inhibition on OM pharmacokinetics and the potential for...